Breaking News Instant updates and real-time market news.

ATVI

Activision Blizzard

$51.35

0.52 (1.02%)

09:14
01/11/19
01/11
09:14
01/11/19
09:14

Activision likely decided to end Bungie agreement, says William Blair

William Blair analyst Ralph Schackart believes the end of the Bungie partnership was likely an Activision Blizzard-driven decision, as Destiny 2 had been underperforming commercial expectations. Despite solid unit sales, it appears the game did not meet expectations on reach and in-game monetization, Schackart tells investors in a research note. He imagines Activision will redeploy developers earmarked to Destiny to existing or new intellectual property that is fully owned. However, the analyst believes last night's announcement, which follows recent management departures, will create more near-term uncertainty. Looking forward, three Blizzard games, Overwatch, Hearthstone, and World of Warcraft are likely to decline in 2019, which made Activision's performance during the year particularly important, says Schackart. Nonetheless, he believes Activision "will ultimately manage through the recent near-term headwinds." He keeps an Outperform rating on Activision Blizzard.

  • 12

    Feb

ATVI Activision Blizzard
$51.35

0.52 (1.02%)

01/11/19
STFL
01/11/19
NO CHANGE
STFL
Buy
Stifel sees limited FY19 financial impact to Activision from giving up Destiny
After Activision Blizzard announced last night that it plans for Bungie to assume full publishing rights for the Destiny franchise, Stifel analyst Drew Crum said he thinks the financial impact on his published 2019 estimates will be limited. The separation makes sense, as the relationship with Bungie seemingly deteriorated following what Activision management described as a disappointing performance for "Destiny 2: Forsaken" and Crum thinks this should free up resources to develop new IP and support existing franchises, such as Call of Duty live services, he said. He maintains a Buy rating on Activision Blizzard shares.
01/11/19
MSCO
01/11/19
NO CHANGE
MSCO
Overweight
More pipeline uncertainty to weigh on Activision multiple, says Morgan Stanley
After Activision Blizzard announced that Bungie would be taking over full publishing rights and responsibilities for the Destiny franchise, Morgan Stanley analyst Brian Nowak said he views this as in part due to a decision to reallocate resources away from Destiny, which has been recently underperforming the company's and his expectations. He estimates the impact to 2019 EPS to be only about 3%, but thinks that higher pipeline uncertainty, recent execution missteps and management departures will weigh on the stock's multiple. Nowak keeps an Overweight rating on Activision Blizzard shares, but said his model in under review.
01/11/19
MKMP
01/11/19
NO CHANGE
Target $48
MKMP
Neutral
Activision Blizzard price target lowered to $48 from $68 at MKM Partners
MKM Partners analyst Eric Handler lowered his price target on Activision Blizzard to $48 and kept his Neutral rating, citing the company's "reduced financial visibility and limited capital appreciation potential" for 2019. The analyst notes that the company's portfolio is "in need of being reinvigorated, especially with Live Service", but expects 2019 to be a year of transition for Activision Blizzard as it scales down its "non-franchise games". Handler further warns that the company's earnings could decline by high-single to low-double digits in FY19, which would require a "significant downward revision in Street estimates."
01/11/19
BMOC
01/11/19
NO CHANGE
Target $52
BMOC
Market Perform
Activision Blizzard price target lowered to $52 from $60 at BMO Capital
BMO Capital analyst Gerrick Johnson lowered his price target on Activision Blizzard to $52 after its announcement that it will turn the development rights to Destiny franchise to Bungie. The analyst also lowers his FY19 EPS view by 5c to $2.60 to reflect the decision while keeping his Market Perform rating on the stock. Johnson adds that while the economics of publishing Destiny games may have turned, he ponders whether the move is "too soon on what, just a few years ago, seemed a crown jewel in the Activision Publishing portfolio."

TODAY'S FREE FLY STORIES

MS

Morgan Stanley

$42.16

-0.24 (-0.57%)

07:21
01/24/19
01/24
07:21
01/24/19
07:21
Hot Stocks
Morgan Stanley CEO: Shutdown could have 'extremely damaging' impact »

Gorman is speaking to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAH

Platform Specialty Products

$10.90

-0.15 (-1.36%)

07:19
01/24/19
01/24
07:19
01/24/19
07:19
Hot Stocks
Platform Specialty Products receives regulatory approval for Arysta sale »

Platform Specialty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MB

Mindbody

$36.41

-0.19 (-0.52%)

07:19
01/24/19
01/24
07:19
01/24/19
07:19
Downgrade
Mindbody rating change  »

JMP downgrades Mindbody…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PANW

Palo Alto Networks

$205.77

2.77 (1.36%)

07:18
01/24/19
01/24
07:18
01/24/19
07:18
Upgrade
Palo Alto Networks rating change  »

Palo Alto Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Feb

PG

Procter & Gamble

$94.87

4.37 (4.83%)

07:18
01/24/19
01/24
07:18
01/24/19
07:18
Recommendations
Procter & Gamble analyst commentary  »

Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 03

    Mar

NMCI

Navios Maritime Containers

$3.03

(0.00%)

07:17
01/24/19
01/24
07:17
01/24/19
07:17
Hot Stocks
Navios Maritime Containers exercises option to acquire containership for $52.5M »

Navios Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAPR

Capricor Therapeutics

$0.58

-0.0751 (-11.46%)

07:17
01/24/19
01/24
07:17
01/24/19
07:17
Hot Stocks
Capricor Therapeutics announces HOPE-Duchenne trial results published »

Neurology, an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$95.49

-1.05 (-1.09%)

07:17
01/24/19
01/24
07:17
01/24/19
07:17
Recommendations
Texas Instruments analyst commentary  »

Texas Instruments price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

NESRF

Northern Star Resources

$0.00

(0.00%)

07:16
01/24/19
01/24
07:16
01/24/19
07:16
Downgrade
Northern Star Resources rating change  »

Northern Star Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:15
01/24/19
01/24
07:15
01/24/19
07:15
General news
FX Update: The dollar has posted advances »

FX Update: The dollar has…

EEX

Emerald Expositions Events

, RELX

RELX

$21.78

-0.03 (-0.14%)

07:14
01/24/19
01/24
07:14
01/24/19
07:14
Recommendations
Emerald Expositions Events, RELX analyst commentary  »

Emerald Expositions a…

EEX

Emerald Expositions Events

RELX

RELX

$21.78

-0.03 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$94.87

4.37 (4.83%)

, EL

Estee Lauder

$126.94

1.19 (0.95%)

07:14
01/24/19
01/24
07:14
01/24/19
07:14
Recommendations
Procter & Gamble, Estee Lauder, Church & Dwight analyst commentary  »

P&G report has…

PG

Procter & Gamble

$94.87

4.37 (4.83%)

EL

Estee Lauder

$126.94

1.19 (0.95%)

CHD

Church & Dwight

$65.45

-0.7 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 05

    Feb

  • 18

    Feb

  • 03

    Mar

  • 28

    May

USAP

Universal Stainless & Alloy

$14.62

-0.515 (-3.40%)

07:14
01/24/19
01/24
07:14
01/24/19
07:14
Hot Stocks
Universal Stainless & Alloy increases low alloy VAR bar base price 5%-10% »

Universal Stainless &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$89.55

-0.89 (-0.98%)

07:12
01/24/19
01/24
07:12
01/24/19
07:12
Recommendations
Xilinx analyst commentary  »

Xilinx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

CNOB

ConnectOne Bancorp

$20.08

-0.19 (-0.94%)

07:11
01/24/19
01/24
07:11
01/24/19
07:11
Earnings
ConnectOne Bancorp reports Q4 adj. EPS 59c, consensus 55c »

As of December 31, 2018,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AEP

American Electric

$77.00

0.65 (0.85%)

07:11
01/24/19
01/24
07:11
01/24/19
07:11
Earnings
Breaking Earnings news story on American Electric »

American Electric backs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AEP

American Electric

$77.00

0.65 (0.85%)

07:10
01/24/19
01/24
07:10
01/24/19
07:10
Earnings
American Electric reports Q4 EPS 74c, consensus 71c »

Reports Q4 revenue $3.8B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

LVS

Las Vegas Sands

$57.25

0.26 (0.46%)

07:10
01/24/19
01/24
07:10
01/24/19
07:10
Recommendations
Las Vegas Sands analyst commentary  »

Las Vegas Sands price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

CNCE

Concert Pharmaceuticals

$14.02

-0.26 (-1.82%)

07:10
01/24/19
01/24
07:10
01/24/19
07:10
Hot Stocks
Concert Pharmaceuticals initiates Phase 1 single-ascending dose trial of CTP-692 »

Concert Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 30

    Jan

  • 12

    Feb

  • 13

    Feb

MDR

McDermott

$8.49

0.01 (0.12%)

07:09
01/24/19
01/24
07:09
01/24/19
07:09
Hot Stocks
McDermott announces ethylene furnace award in Indonesia »

McDermott announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

BWB

Bridgewater Bancshares

$10.41

-0.17 (-1.61%)

07:09
01/24/19
01/24
07:09
01/24/19
07:09
Earnings
Bridgewater Bancshares reports Q4 EPS 25c, two est. 23c »

The fourth quarter of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLDC

China Lending Corp.

$1.11

-0.005 (-0.45%)

07:09
01/24/19
01/24
07:09
01/24/19
07:09
Hot Stocks
China Lending Corp. acquires minority interest in financial service company »

China Lending Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

RCI

Rogers Communications

$54.51

-0.12 (-0.22%)

07:09
01/24/19
01/24
07:09
01/24/19
07:09
Earnings
Rogers Communications sees FY19 revenue up 3%-5% »

Sees FY19 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

LIVX

LiveXLive Media

$6.25

-0.05 (-0.79%)

07:08
01/24/19
01/24
07:08
01/24/19
07:08
Recommendations
LiveXLive Media analyst commentary  »

LiveXLive Media price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRIS

Curis

$1.06

-0.045 (-4.09%)

07:08
01/24/19
01/24
07:08
01/24/19
07:08
Hot Stocks
Curis says first mesothelioma patient dosed in CA-170 study »

Curis announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.